deltatrials

Galderma R&D Clinical Trials

Sponsors / Galderma R&D

302 ClinicalTrials.gov entries name Galderma R&D as the lead sponsor. The portfolio currently includes 11 recruiting studies, 7 active non-recruiting studies, and 267 completed studies. 7 trials in this portfolio were terminated or withdrawn before completion. The most common reasons cited for termination include slow or insufficient recruitment, business or strategic decisions. Cumulative planned enrollment across all listed trials is 62,806 participants. These counts reflect the current state of the public ClinicalTrials.gov registry.

302
Total Trials
11
Recruiting
7
Other Active
267
Completed
7
Terminated / Withdrawn
62,806
Total Enrollment

Termination reasons: Other57% · Recruitment29% · Business14%

Recent Terminations

  • NCT04269395 Phase PHASE3 Stopped Sep 2021
    Keratosis, Actinic
    "The study was terminated early as per Sponsor's decision"
  • NCT02764411 Phase PHASE3 Stopped Oct 2018
    Capillary Malformations
    "Poor enrollment, lack of feasibility"
  • NCT02396251 Phase NA Stopped Nov 2017
    Facial Tissue Augmentation
    "Sponsor business reasons"
  • NCT03508869 Phase NA Stopped Sep 2017
    Erythema and Flushing Associated With Rosacea
    "sponsor asked site to suspend study."
  • NCT01753830 Phase NA Stopped Feb 2014
    Knee Osteoarthritis
    "Study terminated early due to decision by sponsor"
  • NCT00669071 Phase PHASE4 Stopped Oct 2008
    Melasma
    "Enrollment closed"
  • NCT00716443 Phase PHASE4 Stopped Sep 2008
    Nasolabial Folds
    "Sponsor decision"

Active Trials (7 total)

Top Conditions

Top Locations